We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

65 hedge funds and large institutions have $75.1M invested in ProQR Therapeutics in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 10

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

2% more funds holding

Funds holding: 64 → 65 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.37% less ownership

Funds ownership: 35.68% → 35.31% (-0.37%)

6% less capital invested

Capital invested by funds: $80M → $75.1M (-$4.91M)

Holders
65
Holders Change
+1
Holders Change %
+1.56%
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
10
Increased
23
Reduced
10
Closed
8
Calls
$156K
Puts
–
Net Calls
+$156K
Net Calls Change
+$143K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.64M
2
Aberdeen Group
Aberdeen Group
United Kingdom
+$1.52M
3
IC
Ikarian Capital
Texas
+$1.4M
4
Two Sigma Investments
Two Sigma Investments
New York
+$986K
5
PFM
Privium Fund Management
Netherlands
+$840K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$3.59M
2
SL
Siren LLC
Connecticut
-$3.31M
3
AAA
Affinity Asset Advisors
New York
-$2.68M
4
Macquarie Group
Macquarie Group
Australia
-$1.32M
5
WP
Woodline Partners
California
-$196K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$12.6M – – –
PFM
2
Privium Fund Management
Netherlands
$10.8M +$840K +359,475 +7%
Aberdeen Group
3
Aberdeen Group
United Kingdom
$5.96M +$1.52M +651,853 +28%
AAA
4
Affinity Asset Advisors
New York
$4.96M -$2.68M -1,145,722 -32%
SCM
5
Sio Capital Management
New York
$4.37M +$208K +89,042 +4%
DCM
6
DAFNA Capital Management
California
$3.17M – – –
KCM
7
Kynam Capital Management
New Jersey
$3.16M -$194K -83,145 -5%
IC
8
Ikarian Capital
Texas
$3.01M +$1.4M +600,000 +67%
Morgan Stanley
9
Morgan Stanley
New York
$2.76M -$3.59M -1,534,083 -53%
PIM
10
Platinum Investment Management
Australia
$2.5M – – –
ACH
11
ArrowMark Colorado Holdings
Colorado
$2.35M -$190K -81,512 -7%
MCM
12
M28 Capital Management
Connecticut
$2.06M – – –
Two Sigma Investments
13
Two Sigma Investments
New York
$1.7M +$986K +422,084 +101%
Point72 Asset Management
14
Point72 Asset Management
Connecticut
$1.64M +$149K +63,650 +8%
UBS Group
15
UBS Group
Switzerland
$1.61M +$1.64M +703,114 +744%
NAMI
16
Nomura Asset Management International
Pennsylvania
$1.25M +$1.45M +620,000 New
Walleye Capital
17
Walleye Capital
New York
$1.2M +$140K +59,808 +11%
Citadel Advisors
18
Citadel Advisors
Florida
$1.18M -$172K -73,790 -11%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$914K +$523K +223,800 +98%
Millennium Management
20
Millennium Management
New York
$879K +$454K +194,369 +81%
MAM
21
Monaco Asset Management
Monaco
$866K -$72.9K -31,197 -7%
BFM
22
Boothbay Fund Management
New York
$718K +$250K +106,993 +43%
Raymond James Financial
23
Raymond James Financial
Florida
$693K +$544K +232,616 +211%
Northern Trust
24
Northern Trust
Illinois
$595K – – –
PAI
25
Palo Alto Investors
California
$381K – – –
1
2 3

PRQR Hedge Fund Activity: Q4 2025 in Review

65 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2025, worth a combined $75.1M — down 6.1% from $80M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new PRQR positions and 8 closed out — a net gain of 2 holders — while 23 added to existing stakes and 10 trimmed.

The largest buyer was UBS Group, adding an estimated $1.64M. The largest seller was Morgan Stanley, cutting an estimated $3.59M.

  • 65 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2025, up from 64 in Q3 2025.
  • Funds reported $75.1M of ProQR Therapeutics stock for Q4 2025, down 6.1% quarter-over-quarter.
  • 10 funds opened new ProQR Therapeutics positions in Q4 2025 and 8 closed out, a net change of +2 holders.
  • The largest ProQR Therapeutics buyer in Q4 2025 was UBS Group, an estimated $1.64M added.
  • The largest ProQR Therapeutics seller in Q4 2025 was Morgan Stanley, an estimated $3.59M sold.

Based on aggregated 13F filings for Q4 2025.